Home » Stocks » AKUS

Akouos, Inc. (AKUS)

Stock Price: $14.00 USD 0.24 (1.74%)
Updated Apr 19, 2021 2:37 PM EDT - Market open
Market Cap 473.37M
Revenue (ttm) n/a
Net Income (ttm) -48.60M
Shares Out 34.40M
EPS (ttm) -2.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $14.00
Previous Close $13.76
Change ($) 0.24
Change (%) 1.74%
Day's Open 13.91
Day's Range 13.63 - 14.43
Day's Volume 110,904
52-Week Range 13.16 - 30.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearin...

6 days ago - GlobeNewsWire

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disab...

1 week ago - GlobeNewsWire

- In 2020, continued to advance genetic medicine pipeline with execution of IND-enabling studies for AK-OTOF and general alignment with FDA on the path to a 2022 IND submission for AK-antiVEGF

3 weeks ago - GlobeNewsWire

Akouos (AKUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 weeks ago - Zacks Investment Research

There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they believe they can profit remarkably from their investments after the market has reassesse...

Other stocks mentioned: PMVP, TARA
2 months ago - GuruFocus

About AKUS

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibul... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2020
Stock Exchange
NASDAQ
Ticker Symbol
AKUS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Akouos stock is "Strong Buy." The 12-month stock price forecast is 31.67, which is an increase of 126.21% from the latest price.

Price Target
$31.67
(126.21% upside)
Analyst Consensus: Strong Buy